Quiet today — no notable KOL discussion in the last 48 hours.
Quiet today — no notable KOL discussion in the last 48 hours.
Quiet today — no notable KOL discussion in the last 48 hours.
Physicians are discussing results from the ARC-20 trial of the HIF-2α inhibitor Casdatifan in heavily pretreated ccRCC, noting its activity and the association between HIF-2α biology (tEPO) and clinical benefit. Also highlighted is the ARTO trial, where adding SBRT-MDT to abiraterone + ADT improved OS in oligo-mCRPC. Other topics include a new risk model for predicting BCG-unresponsive NMIBC.
“This trial evaluated the HIF-2α inhibitor Casdatifan in heavily pretreated advanced ccRCC and provides important insights into HIF-2α biology and response.”
— @DrChoueiri · ARC-20 trial in ccRCC · View post ↗
“In ARTO, adding SBRT-MDT to abiraterone + ADT improved OS in oligo-mCRPC.”
— @DrYukselUrun · ARTO trial in mCRPC · View post ↗
“⚡️ New risk model to predict BCG-unresponsive disease or progression in HG Ta/T1 NMIBC (n=2,211; 13 centers).”
— @drenriquegrande · NMIBC risk model · View post ↗Quiet today — no notable KOL discussion in the last 48 hours.
Physicians are discussing final results from the TRANSFORM-1 Phase 3 trial of navitoclax plus ruxolitinib in frontline myelofibrosis. Other key topics include data on CAR-T therapy for relapsed/refractory CNS lymphoma, patient-reported outcomes with tafa-len in R/R DLBCL, and 3-year real-world follow-up for acalabrutinib in first-line CLL.
“CAR-T post ASCT R/R CNS lymphoma #EHA2026 - 27 pts, med age 52, 56% PCNSL, 44% SCNSL - 93% HD-MTX, 70% BTKi refractory, median 10 months ASCT➡️CAR - ORR 85% (CR 81%) - 1-yr PFS 62%, maintained at 2 yrs”
— @majorajay · CAR-T in CNS Lymphoma · View post ↗
“Whole genome sequencing [WGS] to identify novel, clinically relevant findings missed by standard of care for Pts w/ myelodysplastic syndrome [MDS]”
— @mtmdphd · WGS in MDS · View post ↗